Symbols / CMND $0.68 -9.80%
CMND Chart
About
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post-traumatic stress disorder and other health conditions; Polyrizon Ltd. to develop novel intranasal MEAI formulation; and NeuroThera Labs Inc. to develop a therapy for weight loss and Metabolic Dysfunction-Associated Steatotic Liver Disease. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.21M |
| Enterprise Value | -3.68M | Income | -3.86M | Sales | — |
| Book/sh | 7.54 | Cash/sh | 35.33 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.09 | P/C | — |
| EV/EBITDA | 0.65 | EV/Sales | — | Quick Ratio | 1.21 |
| Current Ratio | 1.22 | Debt/Eq | 149.16 | LT Debt/Eq | — |
| EPS (ttm) | -24.12 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -53.11% |
| ROE | -179.39% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.79M |
| Shs Float | 130.53K | Short Float | 5.76% | Short Ratio | 0.26 |
| Short Interest | — | 52W High | 52.40 | 52W Low | 0.59 |
| Beta | -1.05 | Avg Volume | 252.08K | Volume | 541.50K |
| Target Price | — | Recom | None | Prev Close | $0.75 |
| Price | $0.68 | Change | -9.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.68
Latest analyst target
3. DCF / Fair value
$-38.30
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.68
Low
—
High
—
Mean
—
- Non-hallucinogenic AUD drug CMND-100 moves into third trial cohort - Stock Titan Wed, 11 Mar 2026 13
- Clearmind Medicine Inc. Announces 1-for-40 Reverse Share Split to Regain Nasdaq Compliance - Quiver Quantitative Wed, 10 Dec 2025 08
- Clearmind Medicine stock rises after positive safety data in alcohol disorder trial - Investing.com Mon, 24 Nov 2025 08
- Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN Wed, 18 Mar 2026 14
- Why Is Clearmind Stock Down Today? - Sahm Fri, 07 Nov 2025 08
- Why Did Clearmind Medicine Shares Jump 7% In Pre-Market Trading? - Benzinga Wed, 26 Nov 2025 08
- Alcohol use disorder drug from Clearmind moves to higher-dose testing - Stock Titan Wed, 04 Mar 2026 08
- Why Did Clearmind Medicine Shares Plunge 29% After Hours? - webull.com hu, 11 Dec 2025 08
- Clearmind Medicine Inc. Advances Enrollment for Third Cohort in Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative Wed, 11 Mar 2026 13
- Clearmind Medicine (CMND) Stock Soars Thursday: What's Going On? - Benzinga hu, 13 Nov 2025 08
- Clearmind Medicine (Nasdaq: CMND) 1-for-40 split trims shares to 1,499,796 from 59,991,852 - Stock Titan Wed, 10 Dec 2025 08
- Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder Treatment Targeting $20 Billion Market | CMND Stock News - Quiver Quantitative Mon, 10 Nov 2025 08
- Clearmind Medicine stock falls after Phase I/IIa trial safety update - Investing.com Mon, 09 Feb 2026 08
- Experimental alcohol use disorder drug shows no serious side effects in trial - Stock Titan Mon, 09 Feb 2026 08
- Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Rule on Minimum Stockholders’ Equity - Quiver Quantitative Fri, 12 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 109167 | 11790 | — | Stock split or consolidation at price 0.11 per share. | Rootenberg (Alan) | Director of Issuer | — | 2025-05-13 00:00:00 | D |
| 1 | 13454 | 79849 | — | Stock split or consolidation at price 5.94 per share. | Rootenberg (Alan) | Director of Issuer | — | 2025-05-13 00:00:00 | D |
| 2 | 9461 | 9461 | — | Exercise of rights at price 1.00 per share. | Rootenberg (Alan) | Director of Issuer | — | 2025-05-13 00:00:00 | D |
| 3 | 5827 | 5827 | — | Exercise of rights at price 1.00 per share. | Rootenberg (Alan) | Director of Issuer | — | 2025-05-13 00:00:00 | D |
Financials
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 296.47K | 94.97K | -943.68K | -157.04K |
| TaxRateForCalcs | 0.15 | 0.15 | 0.40 | 0.26 |
| NormalizedEBITDA | -5.69M | -5.42M | -6.18M | -6.17M |
| TotalUnusualItems | 1.98M | 633.15K | -2.36M | -599.16K |
| TotalUnusualItemsExcludingGoodwill | 1.98M | 633.15K | -2.36M | -599.16K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -3.86M | -5.25M | -8.62M | -6.89M |
| ReconciledDepreciation | 49.37K | 51.07K | 57.51K | 83.07K |
| EBITDA | -3.72M | -4.79M | -8.54M | -6.77M |
| EBIT | -3.77M | -4.84M | -8.59M | -6.85M |
| NetInterestIncome | 113.37K | 235.06K | 59.17K | -14.42K |
| InterestExpense | 19.54K | 36.16K | 10.89K | 14.42K |
| InterestIncome | 132.91K | 271.22K | 70.07K | 0.00 |
| NormalizedIncome | -5.54M | -5.79M | -7.21M | -6.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -3.86M | -5.25M | -8.62M | -6.89M |
| TotalExpenses | 5.67M | 5.74M | 6.30M | 6.25M |
| DilutedAverageShares | 127.09K | 77.50K | 5.06K | 1.08K |
| BasicAverageShares | 127.09K | 77.50K | 5.06K | 1.08K |
| DilutedEPS | -30.35 | -67.80 | -1.70K | -6.38K |
| BasicEPS | -30.35 | -67.80 | -1.70K | -6.38K |
| DilutedNIAvailtoComStockholders | -3.86M | -5.25M | -8.62M | -6.89M |
| NetIncomeCommonStockholders | -3.86M | -5.25M | -8.62M | -6.89M |
| NetIncome | -3.86M | -5.25M | -8.62M | -6.89M |
| NetIncomeIncludingNoncontrollingInterests | -3.86M | -5.25M | -8.62M | -6.89M |
| NetIncomeContinuousOperations | -3.86M | -5.25M | -8.62M | -6.89M |
| TaxProvision | 70.44K | 377.97K | 17.37K | 29.86K |
| PretaxIncome | -3.79M | -4.88M | -8.60M | -6.87M |
| OtherIncomeExpense | 1.77M | 633.15K | -2.36M | -599.16K |
| OtherNonOperatingIncomeExpenses | -209.20K | |||
| SpecialIncomeCharges | 0.00 | 0.00 | -7.33K | |
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 7.33K | |
| GainOnSaleOfSecurity | 1.98M | 633.15K | -2.36M | -599.16K |
| NetNonOperatingInterestIncomeExpense | 113.37K | 235.06K | 59.17K | -14.42K |
| TotalOtherFinanceCost | -59.17K | 10.59K | ||
| InterestExpenseNonOperating | 19.54K | 36.16K | 10.89K | 14.42K |
| InterestIncomeNonOperating | 132.91K | 271.22K | 70.07K | 0.00 |
| OperatingIncome | -5.67M | -5.74M | -6.30M | -6.25M |
| OperatingExpense | 5.67M | 5.74M | 6.30M | 6.25M |
| DepreciationAmortizationDepletionIncomeStatement | 38.41K | 40.09K | 37.30K | 68.24K |
| DepreciationAndAmortizationInIncomeStatement | 38.41K | 40.09K | 37.30K | 68.24K |
| DepreciationIncomeStatement | 38.41K | 40.09K | 37.30K | 68.24K |
| ResearchAndDevelopment | 2.06M | 1.38M | 1.54M | 3.08M |
| SellingGeneralAndAdministration | 3.57M | 4.32M | 4.72M | 3.10M |
| GeneralAndAdministrativeExpense | 3.57M | 4.32M | 4.72M | 3.10M |
| OtherGandA | 2.51M | 2.82M | 4.08M | 1.91M |
| InsuranceAndClaims | 268.74K | 329.28K | 364.06K | 149.54K |
| SalariesAndWages | 790.28K | 1.18M | 281.56K | 1.04M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 158.08K | 106.63K | 15.18K | 1.10K |
| ShareIssued | 158.08K | 106.63K | 15.18K | 1.10K |
| TotalDebt | 1.78M | 53.14K | 0.00 | 38.39K |
| TangibleBookValue | 1.10M | 3.00M | 864.16K | -1.24M |
| InvestedCapital | 2.95M | 3.11M | 983.47K | -1.11M |
| WorkingCapital | 1.06M | 2.96M | 824.76K | -1.50M |
| NetTangibleAssets | 1.10M | 3.00M | 864.16K | -1.24M |
| CapitalLeaseObligations | 18.80K | 53.14K | 0.00 | 38.39K |
| CommonStockEquity | 1.19M | 3.11M | 983.47K | -1.11M |
| TotalCapitalization | 1.19M | 3.11M | 983.47K | -1.11M |
| TotalEquityGrossMinorityInterest | 1.19M | 3.11M | 983.47K | -1.11M |
| StockholdersEquity | 1.19M | 3.11M | 983.47K | -1.11M |
| OtherEquityInterest | 2.69M | 2.98M | 2.64M | 2.36M |
| GainsLossesNotAffectingRetainedEarnings | -21.25K | -21.25K | -21.25K | -21.25K |
| OtherEquityAdjustments | -21.25K | -21.25K | -21.25K | -21.25K |
| RetainedEarnings | -27.88M | -24.02M | -18.77M | -10.15M |
| CapitalStock | 26.40M | 24.17M | 17.13M | 6.71M |
| CommonStock | 26.40M | 24.17M | 17.13M | 6.71M |
| TotalLiabilitiesNetMinorityInterest | 4.89M | 4.15M | 4.97M | 1.93M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 16.42K | 0.00 | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 16.42K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 16.42K | 0.00 | |
| CurrentLiabilities | 4.89M | 4.13M | 4.97M | 1.93M |
| OtherCurrentLiabilities | 2.37M | 3.52M | 4.31M | 290.57K |
| CurrentDebtAndCapitalLeaseObligation | 1.78M | 36.73K | 38.39K | |
| CurrentCapitalLeaseObligation | 18.80K | 36.73K | 0.00 | 38.39K |
| CurrentDebt | 1.76M | |||
| OtherCurrentBorrowings | 1.76M | |||
| PayablesAndAccruedExpenses | 742.39K | 575.02K | 659.44K | 1.60M |
| Payables | 742.39K | 575.02K | 659.44K | 1.60M |
| DuetoRelatedPartiesCurrent | 60.23K | 48.96K | 42.43K | 206.49K |
| AccountsPayable | 682.16K | 526.06K | 617.00K | 1.40M |
| TotalAssets | 6.08M | 7.26M | 5.95M | 826.41K |
| TotalNonCurrentAssets | 135.33K | 167.18K | 158.71K | 391.72K |
| OtherNonCurrentAssets | 20.56K | 7.19K | 37.67K | 14.65K |
| NonCurrentDeferredAssets | 0.00 | 198.17K | 0.00 | |
| GoodwillAndOtherIntangibleAssets | 97.37K | 108.33K | 119.31K | 130.26K |
| OtherIntangibleAssets | 177.80K | 159.80K | ||
| NetPPE | 17.40K | 51.66K | 1.73K | 48.63K |
| AccumulatedDepreciation | -25.58K | -13.19K | ||
| GrossPPE | 17.40K | 51.66K | 1.73K | 48.63K |
| OtherProperties | 1.73K | 12.90K | 16.60K | |
| BuildingsAndImprovements | 17.40K | 51.66K | 0.00 | 35.73K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 5.95M | 7.09M | 5.79M | 434.69K |
| PrepaidAssets | 39.94K | 44.16K | 40.40K | 14.24K |
| Receivables | 322.31K | 180.88K | 240.32K | 97.92K |
| OtherReceivables | 35.83K | 49.04K | 104.32K | 50.93K |
| DuefromRelatedPartiesCurrent | 286.49K | 131.84K | 136.00K | 46.99K |
| AccountsReceivable | 160.87K | |||
| CashCashEquivalentsAndShortTermInvestments | 5.59M | 6.86M | 5.51M | 322.53K |
| OtherShortTermInvestments | 1.66M | 289.39K | 86.11K | 193.75K |
| CashAndCashEquivalents | 3.92M | 6.57M | 5.43M | 128.78K |
| CashFinancial | 175.77K | 3.71M |
| Line Item | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.73M | -4.86M | -6.30M | -3.73M |
| RepaymentOfDebt | -42.54K | -42.59K | -40.92K | -70.87K |
| IssuanceOfDebt | 2.25M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 2.19M | 11.12M | 582.56K |
| CapitalExpenditure | -5.56K | -169.38K | ||
| InterestPaidSupplementalData | 3.86K | 5.39K | 2.91K | 14.43K |
| IncomeTaxPaidSupplementalData | 229.91K | 306.59K | 12.68K | 0.00 |
| EndCashPosition | 3.92M | 6.57M | 5.43M | 128.78K |
| BeginningCashPosition | 6.57M | 5.43M | 128.78K | 3.37M |
| EffectOfExchangeRateChanges | 3.22K | -11.55K | -37.73K | -22.65K |
| ChangesInCash | -2.65M | 1.16M | 5.34M | -3.22M |
| FinancingCashFlow | 2.62M | 6.25M | 11.66M | 511.69K |
| CashFlowFromContinuingFinancingActivities | 2.62M | 6.25M | 11.66M | 511.69K |
| NetOtherFinancingCharges | -600.49K | |||
| InterestPaidCFF | -14.47K | 0.00 | ||
| ProceedsFromStockOptionExercised | 415.09K | 4.10M | 590.08K | 0.00 |
| CashDividendsPaid | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 0.00 | 2.19M | 11.12M | 582.56K |
| CommonStockIssuance | 0.00 | 2.19M | 11.12M | 582.56K |
| NetIssuancePaymentsOfDebt | 2.21M | -42.59K | -40.92K | -70.87K |
| NetLongTermDebtIssuance | 2.21M | -42.59K | -40.92K | -70.87K |
| LongTermDebtPayments | -42.54K | -42.59K | -40.92K | -70.87K |
| LongTermDebtIssuance | 2.25M | 0.00 | 0.00 | |
| InvestingCashFlow | -542.02K | -238.10K | -26.23K | -5.56K |
| CashFlowFromContinuingInvestingActivities | -542.02K | -238.10K | -26.23K | -5.56K |
| NetOtherInvestingChanges | -13.50K | 33.80K | -26.23K | -14.65K |
| NetInvestmentPurchaseAndSale | -528.52K | -271.90K | 0.00 | 0.00 |
| SaleOfInvestment | 186.07K | 78.50K | 0.00 | 0.00 |
| PurchaseOfInvestment | -714.59K | -350.40K | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -145.09K | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -145.09K | |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | -5.56K | -24.29K |
| PurchaseOfPPE | 0.00 | 0.00 | -5.56K | -24.29K |
| OperatingCashFlow | -4.73M | -4.86M | -6.30M | -3.72M |
| CashFlowFromContinuingOperatingActivities | -4.73M | -4.86M | -6.30M | -3.72M |
| ChangeInWorkingCapital | -39.57K | -130.11K | -969.03K | 1.24M |
| ChangeInOtherWorkingCapital | -144.05K | 7.22K | -167.86K | 200.44K |
| ChangeInPayablesAndAccruedExpense | 82.79K | -198.59K | -620.42K | 913.30K |
| ChangeInPayable | -788.28K | 1.12M | 251.88K | |
| ChangeInAccountPayable | -620.42K | 915.97K | 251.74K | |
| ChangeInPrepaidAssets | 4.44K | -3.69K | -26.13K | 103.03K |
| ChangeInReceivables | 17.25K | 64.95K | -154.62K | 19.94K |
| OtherNonCashItems | 213.05K | 5.39K | 2.91K | 14.43K |
| StockBasedCompensation | 805.89K | 998.92K | 834.81K | 1.21M |
| UnrealizedGainLossOnInvestmentSecurities | -844.50K | 68.62K | 107.64K | 308.19K |
| AssetImpairmentCharge | 0.00 | 0.00 | 7.33K | |
| DeferredTax | 70.44K | 103.88K | 17.37K | 29.86K |
| DeferredIncomeTax | 70.44K | 103.88K | 17.37K | 29.86K |
| DepreciationAmortizationDepletion | 49.37K | 51.07K | 57.51K | 83.07K |
| DepreciationAndAmortization | 49.37K | 51.07K | 57.51K | 83.07K |
| AmortizationCashFlow | 10.95K | 10.98K | 10.95K | 14.83K |
| AmortizationOfIntangibles | 10.95K | 10.98K | 10.95K | 14.83K |
| Depreciation | 38.41K | 40.09K | 46.56K | 68.24K |
| OperatingGainsLosses | -1.13M | -701.75K | 2.27M | 290.57K |
| GainLossOnInvestmentSecurities | -1.13M | -707.80K | 2.19M | 290.57K |
| NetForeignCurrencyExchangeGainLoss | -3.61K | 6.05K | 78.17K | 0.00 |
| NetIncomeFromContinuingOperations | -3.86M | -5.25M | -8.62M | -6.89M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CMND
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|